CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses

Nirupama Darshan Verma, Karren Michelle Plain, Masaru Nomura, Giang T Tran, Catherine M Robinson, Rochelle Boyd, Suzanne J Hodgkinson, Bruce M Hall

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Fingerprint

Dive into the research topics of 'CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences